Pancreatic cancer affects roughly 1.7 percent of men and women over a lifetime, making it relatively uncommon compared to cancers of the breast, lung, or colon. In the United States alone, an estimated 67,530 new cases will be diagnosed in 2026. But while it accounts for a small share of all cancer diagnoses, it causes a disproportionately high number of cancer deaths, which is why it gets so much attention relative to its frequency.
Annual Cases and Lifetime Risk
Based on 2021 to 2023 data from the National Cancer Institute’s SEER program, about 1 in 59 Americans will receive a pancreatic cancer diagnosis at some point in their lives. That 1.7 percent lifetime risk applies roughly equally to men and women. For context, the lifetime risk of lung cancer is around 6 percent and breast cancer in women is about 13 percent, so pancreatic cancer is significantly less common than either.
Globally, the picture is larger. GLOBOCAN data from 2022 recorded nearly 511,000 new pancreatic cancer cases worldwide in a single year. Asia accounts for the biggest share at about 45.5 percent of all cases, followed by Europe at 28.7 percent and North America at 13.1 percent. The countries with the highest rates per capita include Uruguay, Hungary, and Armenia.
Why It Gets So Much Attention
Despite being less common than many other cancers, pancreatic cancer is one of the deadliest. Of the roughly 511,000 people diagnosed globally in 2022, about 467,400 died from it that same year. That near 1:1 ratio between new cases and deaths is striking and reflects how difficult it is to catch early and how aggressively it progresses. In the U.S., it consistently ranks among the top causes of cancer death despite not cracking the top ten in new diagnoses.
Not All Pancreatic Cancers Are the Same
When people talk about pancreatic cancer, they almost always mean pancreatic ductal adenocarcinoma, which is the most common and most aggressive type. The other major category, pancreatic neuroendocrine tumors, makes up less than 2 percent of all pancreatic cancers found each year. Neuroendocrine tumors tend to grow more slowly and carry a better prognosis, but they are genuinely rare.
Rates Are Climbing
Pancreatic cancer is becoming more common, not less. Global incidence rates rose roughly 8.9 percent between 1990 and 2021, with prevalence increasing by 16.5 percent over the same period. The trend holds across most regions studied, including the U.S., China, and Japan. Projections through 2030 suggest the U.S. and Japan will experience the greatest increases in pancreatic cancer burden, while rates in South Korea are expected to stay relatively flat.
Researchers haven’t pinpointed a single explanation for the rise. Part of it reflects aging populations and better diagnostic tools catching cases that might have gone unrecorded decades ago. But rising rates of obesity and type 2 diabetes, both established risk factors, likely play a role as well.
Who Is Most at Risk
Pancreatic cancer is overwhelmingly a disease of older adults. Most diagnoses occur after age 65, and it is quite rare in people under 45. Smoking is the single most significant modifiable risk factor, responsible for an estimated 15 to 20 percent of all cases. Long-standing type 2 diabetes, obesity, chronic pancreatitis, and heavy alcohol use also raise risk, though the exact contribution of each is harder to quantify.
Family history matters too. People with two or more first-degree relatives who had pancreatic cancer, or those who carry certain inherited genetic changes, face a meaningfully higher risk than the general population. For these individuals, expert guidelines recommend surveillance using MRI scans or endoscopic ultrasound. A National Cancer Institute study found that monitoring high-risk individuals this way may help detect cancers earlier, when treatment is more effective. For the general population, though, no routine screening test exists, which is a major reason the cancer is so often caught late.
Putting the Numbers in Perspective
A 1.7 percent lifetime risk means that out of 100 people, roughly 98 will never develop pancreatic cancer. It is far less common than cancers of the breast, prostate, lung, or colon. But its lethality makes it punch well above its weight in cancer mortality statistics. The combination of rising incidence, limited screening options, and a narrow window for effective treatment is what drives so much of the concern and research funding directed at this disease.
If you have a strong family history or carry a known genetic predisposition, targeted surveillance is available and may improve outcomes. For everyone else, the most impactful steps are the familiar ones: not smoking, maintaining a healthy weight, and managing blood sugar if you have diabetes.